A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Trial Profile

A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 05 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.
    • 31 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top